Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Net Income towards Common Stockholders (2023 - 2025)

Tonix Pharmaceuticals Holding (TNXP) has 3 years of Net Income towards Common Stockholders data on record, last reported at -$32.0 million in Q3 2025.

  • For Q3 2025, Net Income towards Common Stockholders fell 125.22% year-over-year to -$32.0 million; the TTM value through Sep 2025 reached -$99.2 million, up 26.64%, while the annual FY2024 figure was -$130.0 million, 11.47% down from the prior year.
  • Net Income towards Common Stockholders reached -$32.0 million in Q3 2025 per TNXP's latest filing, down from -$28.3 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at -$14.2 million in Q3 2024 and bottomed at -$78.8 million in Q2 2024.
  • Average Net Income towards Common Stockholders over 3 years is -$29.4 million, with a median of -$28.0 million recorded in 2023.
  • Peak YoY movement for Net Income towards Common Stockholders: tumbled 177.81% in 2024, then surged 64.11% in 2025.
  • A 3-year view of Net Income towards Common Stockholders shows it stood at -$27.3 million in 2023, then rose by 19.08% to -$22.1 million in 2024, then plummeted by 44.79% to -$32.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Income towards Common Stockholders were -$32.0 million in Q3 2025, -$28.3 million in Q2 2025, and -$16.8 million in Q1 2025.